News
Accrufer/Feraccru filed in Canada to treat to treat iron deficiency anaemia.
Shield Therapeutics plc with its lead product Accrufer/Feraccru (ferric maltol), announces that KYE Pharmaceuticals Inc. (‘KYE’) has submitted a New Drug Submission (‘NDS’) to Health Canada for the regulatory review and approval of Accrufer.
If approved, Accrufer would be the first prescription only oral iron therapy approved by Health Canada. Marketing approval for Accrufer is expected to be during first half of 2023.
Condition: Iron Deficiency Anaemia/CKD
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.